City of Hope Appoints Alan H. Bryce, M.D., as Chief Clinical Officer at City of Hope Cancer Center Phoenix and Professor of Molecular Medicine at TGen

PHOENIX–(BUSINESS WIRE)–City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced the appointment of Alan H. Bryce, M.D., as the chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute (TGen), part of City of Hope. He joins City of Hope from Mayo Clinic, where he served as chair of the Division of Hematology and Medical Oncology in the Department of Internal Medicine at Mayo Clinic in Arizona and director of Mayo Clinic Comprehensive Cancer Center in Arizona.

“We are excited to welcome Dr. Bryce to City of Hope Cancer Center Phoenix and look forward to his leadership in delivering advanced cancer care to Arizona patients,” said Kevin Tulipana, D.O., M.S., president of City of Hope Cancer Center Phoenix. “He is an accomplished researcher and clinician who, in addition to his leadership role at City of Hope, will swiftly advance the integration of research and clinical efforts that place the patient first.”

Bryce will serve as the region’s senior clinical leader, guiding care across all City of Hope locations in the Phoenix market, including the cancer center in Goodyear and outpatient care centers in Gilbert, North Phoenix and Tatum Ridge.

He is a world-renowned expert in prostate cancer and has demonstrated how genomics can lead to customized treatment plans that are unique to each individual. He is known for his commitment to patient-centered cancer care, with a focus on reducing health inequities, enhancing patients’ access to top-quality care and protecting patients’ quality of life while continuing research with the goal of curing cancer. Board certified in internal medicine and medical oncology, his clinical focus is prostate cancer, with a special emphasis on individualized medicine, while devoting his research to developing new therapies and genomic-based approaches to prostate cancer.

“This move is motivated by my desire to build a top-quality, coordinated cancer center for the state of Arizona that includes both community and academic practices and enhances access to cancer breakthroughs,” said Bryce. “This is no small task and one where others have tried before, but I am confident that we can succeed. More importantly, this is work that our community needs, and I am excited to meet the challenge.”

At TGen, Bryce will continue his cancer research, new therapeutic development and immunotherapeutic approaches in prostate cancer, with City of Hope Cancer Center Phoenix providing a significant clinical setting to advance scientific discoveries made by TGen. His research focuses primarily on clinical trials, genomics and early therapeutics. Over his career, he has built a robust clinical trials portfolio in genitourinary cancers and melanoma, having launched and led numerous early phase clinical trials to move innovative treatment protocols into the clinic. His interest in genomics lies in the use of tumor sequencing for prognostic and predictive information in advanced cancers. He has also received clinical trial research funding from the National Cancer Institute continuously since 2013.

“I am delighted to welcome Dr. Bryce to City of Hope and TGen,” said Jeffrey M. Trent, Ph.D., TGen president and research director. “I have had the privilege to work closely with him for over a decade, in efforts to use genomics to better individualize a patient’s cancer treatment. His leadership role in national clinical trials for prostate cancer, and the broad range of cancer types for which he has clinical experience (including melanoma and early phase clinical trials), makes him an outstanding addition to City of Hope’s advanced cancer care in Arizona and nationally.”

About City of Hope

City of Hope’s mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and treatment facilities in Atlanta, Chicago and Phoenix. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHope^TM. For more information about City of Hope, follow us on Facebook, Twitter, YouTube, Instagram and LinkedIn.

About TGen, part of City of Hope

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children. Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help patients through efficiency and effectiveness of the translational process. Follow TGen on Facebook, LinkedIn and Twitter.

Contacts

Noah Flack

602-883-1300

[email protected]

Galen Perry

602-343-8423

[email protected]